DelMar Pharmaceuticals, Inc. (DMPI) has announced the presentation of positive preclinical data that demonstrates the potential of its lead bi-functional alkylating agent, VAL-083, in the treatment of ovarian cancer. The results were revealed during the American Association for Cancer Research (AACR) in Ovarian Cancer Research: Exploiting Vulnerabilities Conference.
Based in Vancouver, DelMar is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. "A Comparison of the Mechanisms and Cytotoxic Activity of Dianhydrogalactitol (VAL-083) to Cisplatin in Ovarian Tumor Models Harboring Wild-type and Mutant p53," was conducted in collaboration with MD Anderson Cancer Center. The data supports VAL-083 as an effective treatment option for patients failing platinum-based chemotherapy and demonstrates potential benefit when used along with platinum therapy.
"These data represent another success in our strategy to leverage VAL-083's historical clinical data with contemporary biological research to address significant unmet medical needs in the modern treatment of cancer," said Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals.
This data report follows a number of positive announcements for the company. In late September, DelMar announced an upcoming presentation on the potential effectiveness of VAL-083 in treating children with brain tumors. Also, the company will reveal the next step in their anti-cancer research as the 14th Annual Bio Investor Forum.
"Onset of drug resistance is a major factor limiting the clinical utility of platinum-based therapeutic regimens. Such regimens form the basis of ovarian cancer treatment and produce an initial 70% response rate. Unfortunately, many patients experience relapse as their cancer becomes resistant to currently available chemotherapy. The average duration of survival after recurrence of ovarian cancer is about 12 to 18 months with fewer than one in ten patients surviving beyond five years following standard salvage chemotherapy treatment," said Bacha. "We believe that these data, coupled with evidence of historical clinical activity against ovarian cancer, represent the promise of VAL-083 to address a major modern unmet medical need by providing a potential new treatment option for ovarian cancer patients whose tumors exhibit resistance to platinum-based therapy."
Discovering effective treatments for various cancers is an ongoing effort in the medical community. Through anti-cancer studies, like those conducted by DelMar Pharmaceuticals, each positive result in one step closer to providing patients with hope.
For more information about DelMar Pharmaceuticals, visit www.delmarpharma.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer